Finance

Lists
Why is MPLT up 4.47%?
Dive Deeper
MPLT:NASDAQ
MapLight Therapeutics Inc
$9.69
+4.47%
(+0.41) 1D
$9.70
+0.10% (+0.010)
Pre-market
Closed: Oct 6, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MPLT...
Open
$9.24
High
$9.97
Low
$8.92
Mkt. cap
569.87M
Avg. vol.
553.98K
Volume
143.00
52-wk high
$40.43
52-wk low
$8.92
EPS
-$12.54
Shares outstanding
52.85M
No. of employees
133
Open
$9.24
High
$9.97
Low
$8.92
Mkt. cap
569.87M
Avg. vol.
553.98K
Volume
143.00
52-wk high
$40.43
52-wk low
$8.92
EPS
-$12.54
Shares outstanding
52.85M
No. of employees
133
News stories
From web sources and news partners
About MapLight Therapeutics Inc
CEO-
Employees133
Founded2018
HeadquartersRedwood City, California, United States
SectorBiotechnology
Websitemaplightrx.com
Analyst ratings
Based on 10 analysts giving stock ratings to MPLT in the past 3 months
Buy
Buy
7
Hold
3
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for MPLT in the last 3 months.
Highest
Current $9.69
$43.00 (+343.76%)
Average
$26.00 (+168.32%)
Lowest
$13.00 (+34.16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yatin Suneja
Guggenheim
Hold
Initiated
-
-
10/05/2026
Unknown Analyst
Guggenheim
Hold
Initiated
-
-
10/05/2026
Ami Fadia
Needham
Buy
Reiterated
$43.00
+343.8%
08/31/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
$21.00
+116.7%
08/17/2026
Francois Brisebois
LifeSci Capital
Buy
Maintained
$37.00
+281.8%
08/14/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$20.00
+106.4%
08/13/2026
Malcolm Hoffman
BMO Capital
Buy
Maintained
$20.00
+106.4%
08/13/2026
Ashwani Verma
UBS
Hold
Downgraded
$13.00
+34.2%
08/11/2026
Unknown Analyst
Jefferies
Buy
Maintained
$25.00
+158%
07/30/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
$25.00
+158%
07/28/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$26.00
+168.3%
07/28/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Maintained
$24.00
+147.7%
07/27/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$46.00
+374.7%
07/20/2026
Tiago Fauth
Raymond James
Buy
Initiated
$46.00
+374.7%
06/25/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$36.00
+271.5%
06/02/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/14/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.32 / -$1.29
-2.36%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27.09M
64.62M
53.68M
53.44M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.40M
18.75M
10.82M
10.11M
Operating expense
31.50M
83.38M
64.50M
63.55M
Total operating expenses
31.50M
83.38M
64.50M
63.55M
Operating income
-31.50M
-83.38M
-64.50M
-63.55M
Other non operating income
531.00K
-83.00K
549.00K
1.01M
EBT including unusual items
-29.42M
-79.55M
-60.67M
-60.19M
EBT excluding unusual items
-29.42M
-80.99M
-61.48M
-60.19M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-29.42M
-79.55M
-60.67M
-60.19M
Net profit margin
-
-
-
-
Earnings per share
-
-2.47
-1.34
-1.32
Interest and investment income
1.55M
2.47M
2.47M
2.35M
Interest expense
-
-
-
-
Net interest expenses
1.55M
2.47M
2.47M
2.35M
Depreciation and amortization charges
-
-
-
-
EBITDA
-31.36M
-83.24M
-64.34M
-63.40M
Gain or loss from assets sale
7.00K
-
4.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps